ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...

Shortly after scoring an FDA approval for its Amplatzer Amulet structural heart device this month, Abbott delivered late-breaking clinical trial data putting it up against its main competitor, Boston ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...

Abbott has received a new, broad approval from the FDA for its tiny heart plug implant to help cut down the risk of stroke among people with atrial fibrillation, the most common cardiac arrhythmia.

Abbott Laboratories ABT recently received the FDA go-ahead for its Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

New Guidelines Issued for Management of Atrial Fibrillation The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology. Using dual-seal ...

The U.S. FDA has given its nod for a new trial of Abbott Laboratories’ Amplatzer Amulet left atrial appendage (LAA) occluder for those with atrial fibrillation (AF) who are at risk of stroke. Known as ...

Abbott Laboratories will go toe-to-toe with competitor Boston Scientific after getting approval from the Food and Drug Administration for a device intended to prevent strokes in people with atrial ...

Abbott Laboratories received FDA approval for its Amplatzer Amulet left atrial appendage occluder to treat people with atrial fibrillation who are at risk of ischemic stroke about a month earlier than ...

The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...